Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled

NCT04529525 is registered in ClinicalTrials.gov with Instituto de Cardiología de Corrientes as lead sponsor.

NCT NCT04529525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04529525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled
Lead sponsor
Instituto de Cardiología de Corrientes
Phase
Phase 2/3
Overall status
Completed
Start date
August 19, 2020
Completion date
February 22, 2021
Enrollment
501 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19